- Home
- PYPD vs IMNN Comparison
PYPD vs IMNN Comparison
Compare PYPD & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- IMNN
- Stock Information
- Founded
- PYPD 2008
- IMNN 1982
- Country
- PYPD Israel
- IMNN United States
- Employees
- PYPD N/A
- IMNN N/A
- Industry
- PYPD Medical/Dental Instruments
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- IMNN Health Care
- Exchange
- PYPD Nasdaq
- IMNN Nasdaq
- Market Cap
- PYPD 35.3M
- IMNN 12.1M
- IPO Year
- PYPD 2020
- IMNN 1985
- Fundamental
- Price
- PYPD $3.49
- IMNN $0.80
- Analyst Decision
- PYPD Strong Buy
- IMNN Buy
- Analyst Count
- PYPD 5
- IMNN 2
- Target Price
- PYPD $11.40
- IMNN $14.00
- AVG Volume (30 Days)
- PYPD 1.4M
- IMNN 2.6M
- Earning Date
- PYPD 08-13-2025
- IMNN 08-13-2025
- Dividend Yield
- PYPD N/A
- IMNN N/A
- EPS Growth
- PYPD N/A
- IMNN N/A
- EPS
- PYPD N/A
- IMNN N/A
- Revenue
- PYPD N/A
- IMNN N/A
- Revenue This Year
- PYPD N/A
- IMNN N/A
- Revenue Next Year
- PYPD N/A
- IMNN N/A
- P/E Ratio
- PYPD N/A
- IMNN N/A
- Revenue Growth
- PYPD N/A
- IMNN N/A
- 52 Week Low
- PYPD $2.30
- IMNN $0.37
- 52 Week High
- PYPD $4.42
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- PYPD 55.68
- IMNN 41.12
- Support Level
- PYPD $3.42
- IMNN $0.70
- Resistance Level
- PYPD $3.62
- IMNN $0.86
- Average True Range (ATR)
- PYPD 0.19
- IMNN 0.10
- MACD
- PYPD -0.02
- IMNN -0.06
- Stochastic Oscillator
- PYPD 58.92
- IMNN 10.31
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).